Physician profile
Ayman E Tadros
NPI 1205938974
$3,025.80
in general payments reported to CMS, 2019-2025
27 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.41 · 2020: $151 · 2021: $415 · 2022: $597 · 2023: $471 · 2024: $554 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.08 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $732.28 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $606.68 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $407.11 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $367.75 | 2019-2025 | |
| Exact Sciences Corporation | $134.13 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $124.93 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.15 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.17 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $71.24 | 2022-2023 | Rexulti |
| Glaxosmithkline, LLC. | $55.47 | 2019-2025 | Arexvy |
| E.R. Squibb & Sons, L.L.C. | $34.66 | 2021-2023 | |
| Allergan, INC. | $27.73 | 2020 | |
| Alexion Pharmaceuticals, INC. | $26.22 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.83 | 2022 | |
| Biogen, INC. | $22.24 | 2023 | Skyclarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $22.15 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $21.70 | 2025 | Nuzyra |
| Dexcom, INC. | $19.53 | 2021 | |
| Cardiovascular Systems INC. | $16.32 | 2021 | |
| Abbott Laboratories | $16.24 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
| Lundbeck LLC | $15.02 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $14.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.26 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.56 | 2022 | |
| Sanofi Pasteur INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Tadros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.